FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DIVISLAB Consensus Forecast

No. of reports in last year
4
No. of analysts
2
Average Consensus Forecast
2011.25
Consensus Potential
-13.37%

DIVISLAB Price Target Potential

BrokerageTargetPotential
Karvy Stock Broking2071-8.22%
Sharekhan24307.77%

DIVISLAB Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for DIVISLAB
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

DIVISLAB Ratings

Long term DIVISLAB rating by FrontPage users
4/5 (2 Ratings)

4 DIVISLAB share price target reports by brokerages below. See what is analyst's view on DIVISLAB share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. DIVISLAB Forum
  3. DIVISLAB Price Target

DIVISLAB Share Price Target

DIVISLAB Share Price Target - Broker Reports - 2020

8-Jun-20
Price @ Call: 2381.66
Target: 2071
SELL
We downgrade our revenue estimates for FY21E by 5.9% to Rs. 60.3 bn due to downgrade in Customs Synthesis and Generics business due to no revenue guidance provided by the management. We introduce FY22E revenues at Rs. 72 4 bn. We downgrade our EBITDA margins by 160 bps to 34.4% for FY21E and introduce FY22E EBITDA margins at 36.2%. We downgrade our EPS estimates for FY21E by 10.1%to Rs. 55.1 while we introduce FY 22E EPS estimates at Rs. 71.3 respectively. We roll over our price target to Rs. 2071 based on 29x FY22E (5 year average one year forward PE) and maintain our “SELL” rating.
... Read more
20-Feb-20
Price @ Call: 2201.55
Target: 2430
BUY
Maintain Buy with a revised PT of Rs 2,430: Divis is one of the few pharma companies which is in a sweet spot to capitalize on the opportunities in the API space. A strong run up in the API prices in the recent past is attributable to likely supply disruption from China (due to outbreak of the Corona Virus), a leading supplier of API’s globally and accounting for 20% of the global output. Further, in order to avoid disruptions going ahead, companies globally are evaluating alternate sources for procurement and this is likely to be a key positive for Divis. Also we expect the company to benefit from backward integration, an aggressive capex plan incurred in the past and outsourcing opportunities. Further The company does not have pending regulatory hurdles which is a key positive and offers visibility for growth going ahead. We expect the sales and PAT to grow CAGR 20% and 24% respectively over FY2020 –FY2022. At CMP, the stock is trading at a reasonable P/E multiple of 33x / 26.8x its FY2021E/FY2022E, which is lower than the long term historical average multiple. We Maintain Buy recommendation on the stock with revised PT of Rs 2,430.
... Read more

DIVISLAB Share Price Target - Broker Reports - 2019

19-Aug-19
Price @ Call: 1500.15
Target: 1800
BUY
Maintain Buy with marginally lower PT of Rs. 1,800:
The stock is down by 13-14% from its high and is trading at 21.6x its FY2021E earnings. Although Q1FY2020 performance was below our estimates, we feel long-term growth is likely to remain healthy, led by aggressive capacity expansion plans to monetise opportunities in the U.S. and China. However, taking into account lowered OPM guidance, we have reduced our earnings estimates by 5%/6% for FY2020E and FY2021E,respectively. We expect the company to report sales and profit CAGRs of21% and 18%, respectively, during FY2019-FY2021E. We maintain our Buy rating on the stock with marginally lower PT of Rs. 1,800.
... Read more
12-Aug-19
Price @ Call: 1666.75
Target: 1744
HOLD
Lower margins, limited upside
We downgrade our revenue estimates for FY20E/FY21E by 2.9%/3% due to downgrade in Customs Synthesis and Generics business. We downgrade our EBITDA margins by 190 bps/130 bps to Rs 36.2/ Rs 36.7 for FY20E/FY21E. We downgrade our EPS estimates for FY20E/FY21E by 5.1%/4.2% to Rs54/ Rs64.3 respectively. We downgrade our price target to Rs 1744 based on 27x FY21E and maintain our HOLD rating.
... Read more
28-May-19
Price @ Call: 1593.35
Target: 1780
HOLD
As per the management, Q4 margins were just a kind of aberration. The management continues to expect normalised margins, going forward. On the capex front, to further augment capacities besides preparing for growing opportunities arising due to China factor, the company has earmarked an aggressive capex of ~Rs 1700 crore, over and above ~ Rs 2000 crore spent in the last five years. Margins are also likely to get support from extensive backward integration, product mix and operating leverage. We ascribe a target price of Rs 1780 based on 26x FY21E EPS of Rs 68.4.
... Read more
4-Feb-19
Price @ Call: 1592.98
Target: 1800
BUY

DIVISLAB Share Price Target - Broker Reports - 2018

5-Dec-18
Price @ Call: 1481.21
Target: 1600
BUY
17-Sep-18
Price @ Call: 1305
Target: 1670
BUY
7-Aug-18
Price @ Call: 1194.2
Target: 1455
BUY
6-Aug-18
Price @ Call: 1210
Target: 1380
BUY
6-Aug-18
Price @ Call: 1210
Target: 1270
NEUTRAL
28-May-18
Price @ Call: 1114.84
Target: 1200
NEUTRAL
29-May-18
Price @ Call: 1092
Target: 1020
BOOK PROFIT
15-Mar-18
Price @ Call: 1059
Target: 1275
BUY
29-Jan-18
Price @ Call: 1095.91
Target: 1020
REDUCE

DIVISLAB Share Price Target - Broker Reports - 2017

13-Nov-17
Price @ Call: 997.21
Target: 1275
BUY
7-Nov-17
Price @ Call: 1049.5
Target: 1090
HOLD
3-Nov-17
Price @ Call: 1049.14
Target: 920
REDUCE
2-Nov-17
Price @ Call: 1079.56
Target: 1100
NEUTRAL
16-Oct-17
Price @ Call: 873.19
Target: 1070
BUY
6-Oct-17
Price @ Call: 863.5
Target: 1080
BUY
26-Sep-17
Price @ Call: 952.1
Target: 1040
HOLD
21-Sep-17
Price @ Call: 942.75
Target: 1600
BUY
6-Sep-17
Price @ Call: 723.65
Target: 545
REDUCE
6-Feb-17
Price @ Call: 761
Target: 815
NEUTRAL
3-Feb-17
Price @ Call: 760
Target: 1000
BUY
3-Feb-17
Price @ Call: 760.35
Target: 1120
BUY

DIVISLAB Share Price Target - Broker Reports - 2016

7-Dec-16
Price @ Call: 1163.6
Target: 1400
BUY
17-Nov-16
Price @ Call: 1156
Target: 1305
BUY
11-Nov-16
Price @ Call: 1221
Target: 1320
BUY
15-Nov-16
Price @ Call: 1165.9
Target: 1400
BUY
1-Jun-16
Price @ Call: 1100
Target: 1260
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DIVISLAB Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,414.37
    Upside Target 22,328.18
    Upside Target 12,262.42
    Pivot2,176.23
    Downside Target 12,110.47
    Downside Target 22,024.28
    Downside Target 31,958.52
  • DIVISLAB Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,497.83
    Upside Target 22,454.92
    Upside Target 12,402.83
    Pivot2,359.92
    Downside Target 12,307.83
    Downside Target 22,264.92
    Downside Target 32,212.83
  • DIVISLAB Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,726.52
    Upside Target 22,632.23
    Upside Target 12,455.57
    Pivot2,361.28
    Downside Target 12,184.62
    Downside Target 22,090.33
    Downside Target 31,913.67
  • DIVISLAB Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,328.18
    Upside Target 22,270.14
    Upside Target 12,234.28
    Pivot2,176.23
    Downside Target 12,118.19
    Downside Target 22,082.33
    Downside Target 32,024.28
  • DIVISLAB Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,454.92
    Upside Target 22,418.63
    Upside Target 12,396.21
    Pivot2,359.92
    Downside Target 12,323.63
    Downside Target 22,301.21
    Downside Target 32,264.92
  • DIVISLAB Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,632.23
    Upside Target 22,528.73
    Upside Target 12,464.79
    Pivot2,361.28
    Downside Target 12,257.78
    Downside Target 22,193.84
    Downside Target 32,090.33
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020